Abiraterone Acetate and Radium-223 in Castrate-Resistant Prostate Cancer: Finding the Right Treatment at the Right Time - Charles Ryan

Chuck Ryan's presentation on Abriaterone Acetate and Radium-223 and finding the right treatment at the right time for the right patient.  This discussion is lead by reviewing a patient case study and the practical considerations in the use of novel hormonal agents in the post-ADT setting.  Dr. Ryan provides take home points for proactive metastatic castration-restistant prostate thearpy and benefits of radium-223 for life prolongation. 

Biography

Charles J. Ryan, MD